Drug Profile
Anti CD22 chimeric antigen receptor T cell therapy - Shanghai Yake Biotechnology
Alternative Names: CD22-CAR T cell therapy - Shanghai YaKe Biotechnology; CD22-CAR T cellsLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Shanghai YaKe Biotechnology
- Developer Beijing Boren Hospital; Shanghai YaKe Biotechnology; The First Affiliated Hospital of Zhejiang University School of Medicine
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for phase-I development in Haematological-malignancies in China (Parenteral)
- 28 Aug 2020 No recent reports of development identified for clinical-Phase-Unknown development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma(In adolescents, In children) in China (Parenteral, Infusion)
- 31 Jul 2018 Phase-I clinical trials in Haematological malignancies in China (Parenteral) (ChiCTR1800017402)